Some of the manual screening errors identified in this study included marking a tumor HER2 status as unknown when the information was available in the EHR, recording incorrect hormone receptor status (estrogen receptor and/or progesterone receptor values), or failing to include attributes that changed with subsequent testing. This evidence concerns the gene NR4A1 and neoplasm.